Uganda Commits to Expanding Access to Innovative HIV Prevention Methods
The Ugandan Ministry of Health has reaffirmed its commitment to expanding access to new HIV prevention methods, particularly Pre-Exposure Prophylaxis (PrEP) products, following promising trial results. This initiative is part of the country’s broader National HIV Combination Prevention Strategy, which aims to end AIDS as a public health threat by 2030.
Dr. Diana Atwine, permanent secretary at the Ministry of Health, emphasized the importance of bringing innovative HIV prevention methods to the country. “Globally, there are significant advancements in HIV prevention that promise to strengthen the fight against the epidemic. The Ministry of Health is committed to bringing these innovations to the country as part of our ongoing National HIV Combination Prevention Strategy,” she stated.
One of the most promising developments is the injectable PrEP product, Lenacapavir, which is currently under review. Findings from Gilead Sciences’ Purpose 1 trial, involving over 5,000 participants from Uganda and South Africa, showed that Lenacapavir was 100% effective in preventing HIV transmission among women and adolescent girls.
Once approved, Lenacapavir is expected to be a game-changer, reducing the burden of daily pills, minimizing stigma, and easing the pressure on healthcare systems. In the meantime, Uganda continues to provide oral PrEP to individuals at high risk of HIV infection, with over 700,000 people across 635 health facilities having received oral PrEP to date.
The Ministry has also introduced the dapivirine vaginal ring, a long-acting device that provides month-long protection against HIV during vaginal sex. The PrEP ring is currently available at seven public health facilities, thanks to support from the PEPFAR/USAID MOSAIC project.
Furthermore, the Ministry is in the final stages of introducing the injectable cabotegravir (CAB-LA), another long-acting PrEP option. By the end of September 2024, CAB-LA will be available in seven PEPFAR/USAID-supported facilities, with four additional facilities offering it by February 2025, supported by the Global Fund.
Dr. Atwine reiterated the Ministry’s commitment to expanding access to these innovative HIV prevention products, underscoring its dedication to reaching marginalized populations and ensuring that everyone at risk of HIV can access the necessary protection.
